Articles related to IMMUNOTHERAPY

“Myeloid cells are among the first group of immune cells recruited to tumors, but very quickly these tumor-fighting cells turn into tumor-supporting cells.”

“This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.” — Norman Sharpless, MD

Patients receiving pembrolizumab before, during, and after surgery demonstrated longer event-free survival and higher substantial tumor shrinkage rates, with median survival extending from 30.4 to 51.8 months compared to standard care alone.

Global phase 3 study randomized patients with platinum-refractory extensive-stage SCLC to first-in-class bispecific immunotherapy versus regional standard chemotherapy, achieving primary overall survival endpoint with consistent safety profile.

Reed-Sternberg cells harbor chromosome 9p24 amplification encoding PD-1 ligand, creating therapeutic vulnerability exploited by checkpoint inhibitors with remarkable clinical responses.

In mice whose immune cells that lack the ability to recognize flagellin, immune therapy induced long-term control of ovarian tumor growth in almost 80% of animals.